<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342250</url>
  </required_header>
  <id_info>
    <org_study_id>BKCR-LD-1.0(2010)</org_study_id>
    <nct_id>NCT01342250</nct_id>
  </id_info>
  <brief_title>Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis</brief_title>
  <official_title>Phase Ι/Π Study of Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Beike Bio-Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>No.85 Hospital, Changning, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Beike Bio-Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although liver transplantation provide a option to cure patients suffering with decompensated
      liver cirrhosis this condition, lack of donors, postoperative complications, especially
      rejection, and high cost limit its application. Bone marrow derived mesenchymal stem cells
      (BM-MSCs) have been shown to replace hepatocytes in injured liver, effectively rescued
      experimental liver failure and contributed to liver regeneration, which suggest the novel and
      promising therapeutic strategy In this study, the safety and efficacy of human umbilical cord
      mesenchymal stem cells (hUC-MSCs) transplantation for patients with decompensated liver
      cirrhosis will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety and efficacy of human umbilical cord mesenchymal stem cells
      transplantation in patients of decompensated liver cirrhosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 year after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function improvement</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The size of liver and the width of portal venous</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatocellular carcinoma within 1 year</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh score, MELD score,SF36-quality of life (SF36-QOL)</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical symptom improvement(including appetite, debilitation, abdominal distension, edema of lower limbs, et al )</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Conventional plus hUC-MSCs treatment (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional therapy plus hUC-MSCs treatment （medium dose）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional therapy plus hUC-MSCs treatment （high dose）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>conventional therapy plus low dose hUC-MSCs treatment</intervention_name>
    <description>patients will receive the conventional therapy plus low dose hUC-MSCs treatment</description>
    <arm_group_label>Conventional plus hUC-MSCs treatment (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>conventional therapy plus medium dose hUC-MSCs treatment</intervention_name>
    <description>patients will receive conventional therapy plus medium dose hUC-MSCs treatment</description>
    <arm_group_label>conventional therapy plus hUC-MSCs treatment （medium dose）</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>conventional therapy plus high dose hUC-MSCs treatment</intervention_name>
    <description>patients will receive conventional therapy plus high dose hUC-MSCs treatment</description>
    <arm_group_label>conventional therapy plus hUC-MSCs treatment （high dose）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Aged 18-70 years.

          -  Decompensated liver cirrhosis, Child-Pugh B/C (7-12 points); or Meld score≦21.

          -  Expecting lifetime is over 2 months.

          -  Hepatitis B decompensated liver cirrhosis patients need antiviral therapy.

        Exclusion Criteria:

          -  Severe drug allergic history or anaphylaxis.

          -  Severe problems in other vital organs(e.g. the heart, renal or lungs)

          -  Severe problems in psychiatric disease,such as Schizophrenia,et al

          -  Severe bacteria infection.

          -  Malignancies.

          -  Alcoholism or drug abuse.

          -  Plan to have liver transplantation in 3 months.

          -  Pregnancy

          -  Candidates who are participating in other study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chengwei Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>No.85 Hospital, Changning, Shanghai, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Liver Disease Research Center, the Nanjing Military Command (Shanghai 85 Hospital)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200235</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <last_update_submitted>October 13, 2011</last_update_submitted>
  <last_update_submitted_qc>October 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Decompensated Liver Cirrhosis</keyword>
  <keyword>Umbilical Cord Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

